UBS analyst Michael Yee upgraded Gilead (GILD) to Buy from Neutral with a price target of $145, up from $112, after assuming coverage of the name. The firm cites its expectations for “strong” HIV pre-exposure prophylaxis sales from Yeztugo for the upgrade. This should drive revenue and earnings upside as well as increasing confidence in Gilead’s outer-year growth, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead Sciences: PrEP-Led Growth, Easing HIV Overhangs, and Pipeline Upside Support Buy Rating and 2027 Re-Rating Target
- Repare Therapeutics announces Gilead to acquire RP-3467 for up to $30M
- Early notable gainers among liquid option names on December 23rd
- Trump Trade: Trump strikes deals with nine drugmakers to cut prices
- Gilead opt-in ‘significantly de-risks’ Assembly pipeline, says H.C. Wainwright